Immune Profiles Study

This study assesses glioma patient blood methylation longitudinally beginning pre-surgery through other clinically important timepoints. Progression and survival are studied in relation to methylation derived immunologic profiles and other characteristics. For this study, patients scheduled for surgery at University of California San Francisco (UCSF) for a possible newly diagnosed glioma (grades 2-4) or recurrent grade 2/3 glioma were consented and enrolled. Patients had blood collected pre-surgery and, if the pathology results confirm a glioma, every few weeks or months during their treatment (up to 30 total timepoints). Blood immunomethylomic profiles were measured at these timepoints to assess associations with glioma patient outcomes, clinical measures, other known prognostic markers, and imaging characteristics.]]>
Inclusion Criteria: Patients 18 years of age or older who are scheduled for surgery at UCSF for a newly diagnosed glioma (grades 2-4) or recurrent grade 2/3 glioma.Exclusion Criteria: Patients with a diminished capacity to consent for themselvesPatients who do not speak EnglishPatients who do not reside in the United States.]]>